Item 7.01. Regulation FD Disclosure.
As previously announced, Oscar Health, Inc. (the “Company”) will host its 2024 Investor Day on June 7, 2024, beginning at 9:00 a.m. Eastern Time. At the event, the Company will reconfirm the full year 2024 guidance that it provided in its financial results press release for the fourth quarter of 2023 dated February 7, 2024, and will provide an update on Adjusted EBITDA performance through the end of April 2024. In addition, the Company will provide an update on its strategic plans, long-term growth targets and levers available to achieve these targets. There will be a live webcast to the presentation accessible via the Company’s investor relations website at https://ir.hioscar.com. Instructions for accessing the webcast were previously provided in the Company’s press release issued on April 10, 2024 and can also be found on the Company’s investor relations website. A copy of the presentation materials to be presented by the Company at the event will be available on the Company’s investor relations website shortly before the event begins.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our expected financial performance, financial targets and long-term strategy, and upcoming events and presentations. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control. Although management believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”), and our other filings with the SEC. You are cautioned not to place undue reliance on any forward-looking statements made herein. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.
Financial Disclosure Advisory
The preliminary Adjusted EBITDA information that the Company intends to discuss at the event represents information available to the Company’s management through April 30, 2024. Actual results for the second, third and fourth fiscal quarters of 2024 and the year ending December 31, 2024 will depend on the completion of quarter-end accounting procedures and adjustments, including the completion of the Company’s financial statements and the subsequent occurrence or identification of events prior to the filing of our financial results for the relevant period with the SEC.
